{"symbol":"BMY","fiscalQuarter":"Q3-2012","reportDate":"2012-10-24","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2012","postBrief":{"headline":"Bristol Myers Squibb Misses on EPS, Stock Down 0.57%","keyNumbers":[{"metric":"EPS","actual":"$0.41","expected":"N/A","surprise":"-0.97%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed confidence in ongoing product pipeline.","They highlighted the importance of upcoming clinical trial results."],"summary":"Overall, management remains focused on long-term growth despite the slight EPS miss. They emphasized the strength of their product portfolio."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a small decline in the stock price. Investors may be cautious due to the lack of revenue data and forward guidance. The management's focus on the product pipeline suggests they are looking to future growth despite current challenges.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2012 earnings: EPS missed expectations. Stock down 0.57%. Full breakdown."}}